Merck & Co., Inc.
Merck Announces Second-Quarter 2025 Financial Results and New Restructuring Program
Summary
Merck & Co., Inc. reported a 2% decrease in worldwide sales to $15.8 billion for the second quarter of 2025. GAAP EPS was $1.76, and non-GAAP EPS was $2.13. The company approved a new restructuring program expected to yield $1.7 billion in annual cost savings by the end of 2027. Merck also announced an agreement to acquire Verona Pharma for $10 billion, expected to close in the fourth quarter of 2025. The acquisition will add Ohtuvayre, a COPD treatment, to Merck's portfolio.
Profitelligence Alerts
Get alerts for MRK
Be first to know when Merck & Co., Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Merck & Co., Inc.
Merck & Co., Inc. is a prominent player in the global pharmaceutical industry. It is primarily focused on the research, development, production, and marketing of drugs and vaccines. Known for its strong emphasis on innovative health solutions, Merck develops treatments and vaccines for a variety of diseases affecting humans and animals. Key areas include oncology, infectious diseases, diabetes, and vaccines, reflecting its commitment to addressing critical health challenges worldwide. The company operates in several strategic regions, exporting its advanced therapies to meet healthcare needs across different markets. With a robust pipeline of new products and significant investment in research and development, Merck plays a vital role in advancing medical breakthroughs and enhancing patient care. Beyond pharmaceuticals, Merck is involved in animal health, providing veterinary vaccines and services, contributing to agricultural productivity and food security. The company's ongoing efforts in groundbreaking research and public health initiatives underscore its importance in the healthcare sector.
Official SEC Documents
Advertisement